[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,105,0,25,[9,46,59,83,119,160,181,213,257,325,352,398,420,443,511,531,560,579,601,622,649,675,696,719,744],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054224","phase-1-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iodine-non-responsive-oncocytic-hurthle-cell-thyroid-cancer-100054224",false,"NCT06991738","177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","Phase 1\u002F2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged 18 years or older.\n* Metastatic RAI-non-responsive and\u002For RAI-non-avid oncocytic (Hurthle cell) thyroid cancer.\n* Progressive disease by RECIST 1.1 criteria, with or without symptoms within the last 12 months. This applies to patients with non-measurable disease by RECIST 1.1 criteria, who will be eligible if they have evidence of progression as defined by the development of new lesions within the last 12 months.\n* High expression of SSTR2 in at least one metastatic lesion as documented by 68Ga-DOTATATE PET\u002FCT with SUVmax \\> SUVmax of the liver consistent with Krenning score of \\>2 or SUVmax \\>= 13 based on scan performed within 12 weeks of anticipated enrollment.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnant or breastfeeding.\n* NET\u002FPET score of 5 by imaging with 68Ga-DOTATATE PET\u002FCT and 18FDG-PET\u002FCT and defined more than 2 lesions that are SSTR2 negative but 18FDG positive and\u002For more than 2 lesions that have significantly higher uptake of 18FDG than 68Ga-DOTATATE\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-EB-TATE as assessed from medical record.\n* Patient weight \\> 500 lbs. (due to the PET scanner table limit).\n* Inability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRI.\n* Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 4 weeks or 4 half-lives (whichever is longer), before the first administration of study drug.\n* Previous surgery \\\u003C 6 weeks prior to the start of participation in this study, or participant has not fully recovered from major surgery, or has suffered significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug.\n* Life expectancy \\\u003C 6 months as assessed by the treating physician.\n* Karnofsky performance status scale \\\u003C 70%.\n* Inability or unwillingness to use adequate contraception prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men). The adequate contraception consists of intrauterine device, contraceptive implant, hormonal contraception or a double-barrier method. If the patient is status post tubal ligation, status post hysterectomy and\u002For oophorectomy, or their male partners are status post vasectomy, no additional method of contraception is required.\n* Deteriorated renal function, as indicated by a creatinine clearance \\\u003C60 mL\u002Fmin calculated by the Cockcroft-Gault Equation. The calculated creatinine clearance can be confirmed by measured creatinine clearance.\n* Having only one functional kidney, due to potential nephrotoxicity.\n* Patients who have had any prior EBRT dose to either kidney.\n* Deteriorated bone marrow function, as indicated by:\n\n  * Hemoglobin (Hb) \\\u003C 8.0 g\u002FdL\n  * White blood cell (WBC) \\\u003C 2 x10\\^3\u002FuL\n  * Absolute neutrophil count (ANC) \\\u003C 1.0 x 10\\^3\u002FL\n  * Platelets \\\u003C100 x 10\\^3\u002FmicroL\n* Deteriorated liver function, as indicated by one or more of the following:\n\n  * International normalized ratio (INR) \\> 2.0 for patients that are not on Coumadin\n  * Prothrombin time (PTT) \\> 2 x ULN\n  * Total bilirubin \\> 3 mg\u002FdL\n  * Serum albumin \\\u003C 3.0 g\u002FdL unless prothrombin time is within the normal range\n  * Alanine aminotransferase (ALT) \\> 3 x ULN\n  * Aspartate aminotransferase (AST) \\> 3 x ULN.\n* Previous local therapy \\\u003C4 weeks prior to study entry.\n* Extended QTc interval above 480 ms confirmed by 2 ECGs. If the first ECG conducted at the screening visit shows extended QTc interval, potential participants will be asked to repeat an ECG within 30 days to confirm. The second ECG can be conducted at NIH CC or at their outside provider, at their potential expense.\n* Toxicities from prior therapies that have not resolved to grade 1 or grade 0 excluding dry mouth syndrome from previous RAI and grade 2 anemia\u002Fleukopenia as Hgb\\>=8 g\u002Fdl, WBC \\>=2 x10\\^3\u002FuL and ANC \\>= 1.0 x 10\\^3 are acceptable for enrollment.\n* Active and clinically significant bacterial, fungal, or viral infection, including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness. Radiolabeled ligands may affect the immune response, so people with active and clinically significant infections may become too immunocompromised through participation in this study.\n* Known brain metastases and\u002For carcinomatous meningitis unless these metastases have been treated and stabilized.\n* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Prior external beam radiation therapy involving \\>25% of the bone marrow.\n* Unmanageable urinary incontinence rendering the administration of 177Lu-DOTA-EB-TATE unsafe.\n* Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence.\n* Is unwilling or unable to establish care with a local provider outside of NIH CC\n* Inability to understand or unwilling to sign a written informed consent document.","ALL","18 Years","100 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nOncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.\n\nObjective:\n\nTo test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC.\n\nEligibility:\n\nPeople aged 18 years and older with HTC. The HTC must have failed to respond to conventional radioactive treatment; it must also have spread to other parts of the body.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have imaging scans and a test of their heart function.\n\n177LuDOTA-EB-TATE is infused into a vein. Participants will receive 4 infusions spaced 8 to 12 weeks apart. They will stay in the hospital for 4 to 10 days after each infusion. During and after each infusion, participants will remain in a lead-lined room until their radiation levels go down; this usually takes about 24 hours.\n\nParticipants will have 4 to 6 follow-up visits in the weeks after each infusion. Procedures will vary at each visit, but may include more imaging scans; blood and urine tests; and tests of heart function. Participants will have 2 single-photon emission computerized tomography (SPECT) scans. SPECT scans show where the study drug is sticking to tumors or maybe other parts of their body. They will lie on a table while a machine rotates around them. Participants will fill in questionnaires about how their thyroid condition affects their life.\n\nParticipants will have follow-ups visits for 5 years after their last study treatment.",[29],"Thyroid Cancer",[29,31,32],"H(SqrRoot) rthle cell thyroid cancer","177Lu-DOTA-EB-TATE","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":22},"2026-07-16",{"date":41,"type":22},"2032-08-01",{"name":43,"class":44},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":47,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":49,"briefSummary":27,"conditions":50,"keywords":51,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":45},"100592308",{"count":21,"type":22},[25,26],[29],[29,31,32],"2026-07-01",{"date":54,"type":37},"2026-07-02",{"date":56,"type":22},"2026-07-07",{"date":41,"type":22},{"name":43,"class":44},{"id":60,"slug":61,"hasResults":12,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":45},"100350346","phase-2-the-use-of-124-i-petct-whole-body-and-lesional-dosimetry-in-differentiated-thyroid-cancer-100350346","NCT03841617","The Use of 124-I-PET\u002FCT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","* INCLUSION CRITERIA:\n* Patients with established thyroid cancer diagnosis based on the pathology report reviewed at the National Institutes of Health, who:\n\n  * underwent total thyroidectomy plus or minus neck lymph node dissection as clinically indicated,\n  * are presenting with known per structural imaging (US neck, CT or MRI neck\u002Fchest\u002Fabdomen\u002Fpelvis) persistent\u002Frecurrent disease either locally advanced or presenting with distant metastases; or\n  * are presenting with suspected persistent\u002Frecurrent locoregional or distant metastases based on the high risk features such as advanced tumor per pathology report (tumor size \\>4 cm, exrathyroidal extension, higher risk pathology such as tall cell, columnar cell, poorly differentiated variant, follicular thyroid cancer with gross vascular invasion, positive margins after the surgery, bulky lymphadenopathy in the central and\u002For lateral neck), detectable\u002Fincreasing baseline\u002Fsuppressed thyroglobulin (Tg) level or detectable\u002Fincreasing anti-Tg antibody titers if anti-Tg antibodies are present.\n  * are either RAI -naive or requiring repeated RAI therapy for locally advanced disease or distant metastases or underwent therapy with BRAF inhibitor (dabrafenib or vemurafenib\\*) or selumetinib\\*\\* for at least 4 weeks that may re-induce RAI uptake.\n  * Underwent imaging with either a CT or MRI of the brain and spine with gadolinium contrast to screen for the brain\u002Fspine metastases.\n\n    * Age greater than or equal to 18 years of age.\n    * 24 hour urine iodine excretion of less than or equal to 150 micro grams\u002F24 hour.\n\n      * BRAF inhibitors are recommended by 2021 NCCN guidelines as one of the management options for BRAF mutant tumors(13,14)\n\n        * Selumetinib has an FDA orphan drug designation for adjuvant treatment of metastatic thyroid cancer to re-induce RAI uptake\n\nEXCLUSION CRITERIA:\n\n-Patients with RAI-non avid disease documented by negative post-therapy whole body scans performed after previous RAI treatments and not subjected to re-differentiation therapy.\n\n* Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma, severe depression which might be exacerbated by thyroid hormone withdrawal.\n* Patients with spinal or brain metastases as they are at risk of TSH-stimulation induced swelling of metastatic lesions leading to potentially detrimental side effects. These patients will be evaluated per the standard of care protocol 77-DK-0096.\n\n  * Pregnant or lactating women per self report.\n  * Adults who are incapable of providing informed consent.","90 Years",{"count":67,"type":22},30,[26],"Study rationale\n\nHigh risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation. There are two methods of TSH stimulation endogenous by thyroid hormone withdrawal (THW) leading to hypothyroidism and exogenous by injection of human recombinant TSH (rhTSH Thyrogen). The appropriate 131-I activity utilized for treatment is either based on empiric fixed dosage choice or individually determined activity based on 131 I dosimetric calculations. Although dosimetry utilizing radioactive iodine isotope 131 I enables calculation of maximum safe dose, it does not estimate the tumoricidal activity necessary to destroy the metastatic lesions. The alternative radioactive isotope of iodine -124 I, used for positron emission tomography (PET) imaging, might be used for calculation not only the maximum safe131 I dose, but also to predict the absorbed dose in the metastatic lesions.\n\nStudy objectives\n\nThe primary objective of this study is to compare the 124 I -PET\u002FCT lesional and whole body dosimetry in each individual patient with metastatic radioiodine (RAI)-avid thyroid cancer under preparation with rhTSH and THW. The secondary objective is to evaluate the predicted by PET\u002FCT lesional uptake with the early response to therapy.\n\nStudy design\n\nThis is a phase 2 pilot prospective cohort study comparing the lesional and whole body dosimetry within each patient undergoing exogenous (rhTSH) and endogenous (THW) TSH stimulation and followed for 5 years.\n\nInterventions\n\nEach study participant will undergo rhTSH and THW-aided 124 I-PET\u002FCT dosimetric evaluations and will be subsequently treated with THW-aided RAI activity based on dosimetric calculations enabling maximum safe dosage. The patients will be followed in 12+\u002F-3 months intervals for 5 years.\n\nSample size and population\n\nThis pilot study will include 30 patients with high risk differentiated thyroid cancer presenting with distant and\u002For loco-regional metastases.",[29],[29,72,73,74,75],"PET\u002FCT","124-I","Radioiodine","Metastases","RECRUITING",{"date":54,"type":37},{"date":79,"type":37},"2019-07-29",{"date":81,"type":22},"2035-11-01",{"name":43,"class":44},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":104,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100575356","phase-1-slv-154-treatment-of-metastatic-solid-tumors-100575356","NCT06771219","SLV-154 Treatment of Metastatic Solid Tumors","A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Men or women (as appropriate for cancer type) of age ≥18 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n3. Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records with the primary history comprising one of the following:\n\n   1. SCCHN\n   2. NSCLC\n   3. SCLC\n   4. Breast cancer\n   5. Cervical cancer\n   6. Endometrial cancer\n   7. Ovarian cancer\n   8. Urothelial cancer\n   9. Sarcoma\n   10. Thyroid cancer\n4. Presence of metastatic disease that has progressed during or following previous treatment.\n5. Presence of radiographically measurable disease.\n6. Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.\n7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.\n8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and\u002For fluorodeoxyglucose (FDG) positron emission tomography (PET)\u002FCT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.\n9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.\n10. Adequate hematological profile.\n11. Adequate coagulation profile.\n12. Adequate hepatic profile.\n13. Adequate renal function.\n14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.\n15. For female subjects of childbearing potential, a negative serum pregnancy test.\n16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.\n17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.\n18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy\u002Faspirations and\u002For radiographic studies), and study restrictions.\n19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.\n4. Significant cardiovascular event or comorbidity.\n5. Significant screening ECG abnormalities.\n6. Pregnancy or breastfeeding.\n7. Major surgery within 4 weeks before the start of study therapy.\n8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.\n9. Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.\n10. Concurrent participation in another therapeutic or imaging clinical trial.\n11. Other conditions likely to interfere with a subject's ability to participate in the study.",{"count":91,"type":22},70,[25],"This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.",[95,96,97,98,99,100,101,102,103,29],"Squamous Cell Cancer of Head and Neck (SCCHN)","NSCLC","SCLC","Cervical Cancer Metastatic","Breast Cancer Metastatic","Endometrial Cancer","Ovarian Cancer","Urothelial Cancer","Sarcoma",[105,106,107],"metastatic solid tumors","metastatic cancer","solid tumor","2026-06-29",{"date":110,"type":37},"2026-06-30",{"date":112,"type":37},"2025-05-14",{"date":114,"type":22},"2027-04",{"name":116,"class":117},"Solve Therapeutics","INDUSTRY",10,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":144,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100480603","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-monotherapy-or-in-combination-in-people-with-advanced-solid-tumors-100480603","NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","A PHASE 1A\u002FB OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS","Phase 1b Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor (excluding colorectal cancer)\n* Measurable disease by RECIST version 1.1\n* Evidence of a BRAF V600 mutation\n* Prior therapy per tumor cohort\n* Adequate organ function per protocol\n\nPhase 1b Exclusion Criteria:\n\n* Other active malignancy within 3 years\n* Presence of leptomeningeal disease\n* History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)\n* Active gastrointestinal disease as defined per protocol\n* History of interstitial lung disease as defined per protocol","16 Years",{"count":128,"type":22},124,[25],"The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).\n\nPhase 1a is no longer open for enrollment. In Phase1b (noted as \"this study\"), we are seeking participants who have:\n\n* a solid tumor which is metastatic or recurrent (excluding colorectal cancer)\n* tumor with the mutation (abnormal gene) called \"BRAF V600\"\n* received required prior treatment for cancer per cohort assigned.\n\nAll participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.\n\nParticipants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.",[132,133,29,134,135,136,137,138,139,140,141,142,143],"Melanoma","Glioma","Non-Small Cell Lung Cancer","Malignant Neoplasms","Brain Neoplasms","Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer","NSCLC (Non-small Cell Lung Cancer)",[145,146,147,148,149,150,151],"solid tumors","BRAF","advanced solid tumors","B-Raf","MAPK","neoplasms","BRAF V600",{"date":52,"type":37},{"date":154,"type":37},"2022-11-30",{"date":156,"type":22},"2029-06-18",{"name":158,"class":117},"Pfizer",83,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":126,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},"100466589","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799933-in-people-with-advanced-solid-tumors-with-braf-alterations-100466589","NCT05355701","A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS","This study is seeking participants who meet the following key eligibility criteria:\n\nInclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor including primary brain tumor.\n* Qualifying BRAF alteration (V600 or non-V600 Class II\u002FClass III BRAF alteration), in tumor tissue and\u002For blood (ie circulating tumor deoxyribonucleic acid \\[DNA\\], or ctDNA).\n* Disease progressed during\u002Ffollowing last prior treatment and no satisfactory alternative treatment options (Part 1, Part 2 (doublet), and Part 3 (cohorts 2, 3, 6, 7)).\n* Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies\n* Part 3 (Cohort 1) (BRAF V600 mutant melanoma): Prior BRAF V600 inhibitor therapy required, prior MEK inhibitor therapy required, and immune checkpoint inhibitor therapy required.\n* Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required. No prior BRAF inhibitor\u002FEGFR inhibitor allowed. Participants with MSI-H\u002FdMMR mCRC should receive prior immune checkpoint inhibitor therapy.\n* Part 3 (Cohort 5) (BRAF V600E CRC): No more than 2 cycles of prior 5-FU based chemotherapy allowed. No prior BRAF inhibitor\u002FEGFR inhibitors allowed. Participants with MSI-H\u002FdMMR mCRC should receive prior immune checkpoint inhibitor therapy.\n\nExclusion Criteria:\n\n* Brain metastasis larger than 4 cm\n* Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO; history of retinal degenerative disease.\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK).",{"count":168,"type":22},267,[25],"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.\n\nThis study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called \"BRAF\" and available treatments are no longer effective in controlling their cancer.\n\nAll participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine:\n\n* People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day.\n* People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV).\n\nParticipants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.",[132,172,29,133,173],"Non-Small-Cell Lung Cancer","Advanced Colorectal Cancer (Part 1)",{"date":52,"type":37},{"date":176,"type":37},"2022-07-05",{"date":178,"type":22},"2029-10-25",{"name":158,"class":117},40,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":192,"conditions":193,"keywords":198,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":45},"100625855","postoperative-hypocalcemia-after-thyroidectomy-100625855","NCT07428057","Postoperative Hypocalcemia After Thyroidectomy","A Ten-Year Cohort Study of Clinical and Surgical Predictors for Hypocalcemia Post-Thyroidectomy","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at time of surgery\n* Underwent thyroidectomy at Minia University Hospital\n* Availability of medical records with complete surgical and postoperative data\n* Documented serum calcium levels measured postoperatively\n* Minimum follow-up of 6 months postoperatively or documented outcome status\n\nExclusion Criteria:\n\n* Age less than 18 years at time of surgery\n* Preoperative hypocalcemia (serum calcium \\\u003C8.0 mg\u002FdL or ionized calcium \\\u003C1.0 mmol\u002FL)\n* Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)\n* Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)\n* Concurrent planned parathyroidectomy\n* History of neck irradiation\n* Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)\n* Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data\n* Patients lost to follow-up before 6-month endpoint without documented outcome status","75 Years",{"count":190,"type":22},600,"OBSERVATIONAL","This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.",[194,195,196,29,197],"Thyroid Nodule","Thyroid Dysfunction","Hypocalcemia","Postoperative Complications",[199,200,201,202,203],"Thyroidectomy","Postoperative hypocalcemia","Hypoparathyroidism","Parathyroid gland injury","Total thyroidectomy","2026-06-27",{"date":110,"type":37},{"date":207,"type":37},"2026-03-04",{"date":209,"type":22},"2026-08-01",{"name":211,"class":212},"Minia University","OTHER",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":223,"type":22},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[226,227,228,229,100,230,231,232,233,234,132,235,236,237,101,238,239,240,241,103,242,243,244,29,245,246,247],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-06-26",{"date":108,"type":37},{"date":251,"type":37},"2025-09-18",{"date":253,"type":22},"2028-03-30",{"name":255,"class":117},"AstraZeneca",17,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":264,"sex":17,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":269,"studyType":191,"phases":4,"briefSummary":270,"conditions":271,"keywords":307,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":268,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[238,29,272,230,273,274,275,276,227,277,278,279,280,234,281,282,283,284,228,285,286,239,243,287,245,288,289,290,291,292,293,294,295,241,296,297,298,299,300,301,132,103,302,303,101,100,246,304,305,306],"Lung Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Kidney Cancer","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[238,29,308,309,310,311,312,313,194,314,300,315,305,306],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":108,"type":37},{"date":319,"type":37},"2013-11-01",{"date":321,"type":22},"2099-12",{"name":323,"class":212},"University of Nebraska",42,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100384819","phase-3-systematic-radioiodine-administration-versus-decision-of-radioiodine-treatment-guided-by-a-post-operative-work-up-100384819","NCT04290663","Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up","Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy","INTERMEDIATE","Inclusion Criteria:\n\n* Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017:\n\n  * Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with \\\u003C 4 foci of vascular invasion) or Hürthle cell carcinoma (HCC)\n  * T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and\u002For pN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10\n  * T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10\n* Patient treated by total thyroidectomy with macroscopically complete tumor resection (R0 or R1) ± neck dissection\n* Total thyroidectomy performed within 6 to 14 10 weeks before randomization\n* Patient with or without anti-thyroglobulin antibodies (TgAb)\n* No known distant metastases\n* Normal post-operative neck ultrasound (US) or if doubtful US, negative cytology and normal Tg value (\\\u003C10 ng\u002Fml) in FNA washout fluid\n* Post-operative LT4 treatment initiated at least 6 weeks before randomization\n* Performance Status 0 or 1\n* Patients aged 18 years or older\n* Signed informed consent form\n* Patient who agrees to be followed annually during 5 years\n* Patient affiliated to the French social security system\n\nExclusion Criteria:\n\n* • Patients with:\n\n  * medullary or anaplastic thyroid cancer\n  * or poorly differentiated carcinoma\n  * or well differentiated FTC with at least more than 4 foci of vascular invasion\n  * or PTC with aggressive variants (tall cell or columnar cell carcinoma, diffuse sclerosing papillary, hobnail variant)\n  * NIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear features)\n\n    • Low-risk or high-risk DTC patients according to ATA 2015, and intermediate-risk patients with extra-thyroid extension into the perithyroidal muscles (pT3b according to pTNM 2017), and\u002For pN1 with nodal largest dimension \\>10 mm or with extra-capsular invasion or more than 10 metastatic nodes. This excludes the following patients:\n  * All pT1a, pT3 or pT4\n  * pT1aN0\u002Fx with or without minimal extra-thyroid extension\n  * pT1bN0\u002Fx, pT2N0\u002FNx without minimal extra-thyroid extension\n  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \\\u003C2mm\n  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \\>10mm\n  * pT2N0\u002FNx without extra-thyroid extension\n  * pT2N1 without extra-thyroid extension and with nodal largest dimension \\\u003C2mm\n  * pT2N1 without extra-thyroid extension and with nodal largest dimension \\>10mm\n  * Surgery considered as macroscopically incomplete (R2)\n\n    * Patients who have undergone lobectomy only\n    * Post-operative neck US with metastatic lymph-nodes confirmed by cytology or by increased Tg (\\>10 ng\u002Fml) in FNA washout fluid\n    * Drugs affecting thyroid function including iodinated contrast agents in the 6 weeks prior to randomization. Amiodarone should have been stopped at least 1 year before randomization.\n    * Previous RAI treatment for thyroid cancer\n    * Pregnant or lactating women\n    * Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study\n    * Patient deprived of liberty or placed under the authority of a tutor\n    * History of malignancy in the past 3 years, except skin cancer excluding melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not have shown signs of recurrence for at least 3 years",{"count":334,"type":22},368,[336],"PHASE3","This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy",[29,339],"Intermediate Risk",[341,342],"radioiodine","I131","2026-06-24",{"date":316,"type":37},{"date":346,"type":37},"2020-03-02",{"date":348,"type":22},"2033-02",{"name":350,"class":212},"Centre Francois Baclesse",29,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":363,"conditions":364,"keywords":374,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":397},"100610263","a-study-of-meaning-centered-therapy-for-mexican-adults-with-advanced-cancer-100610263","NCT07225309","A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer","Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer","Patient Eligibility Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment.\n\nInclusion Criteria:\n\nEMR Criteria\n\n\\- Documentation of Disease\n\n* Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis)\n\n  * Definition of Disease \\[or Measurable Disease\\]\n* Diagnosed with stages III or IV\n\n  * Prior Treatment\n* Receiving ambulatory care at INCan\n\nSelf-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nEMR Criteria\n\n* Prior Treatment\n\n  * Received psychological or psychiatric care at INCan in the last 3 months\n  * In the judgment of the treating physician, protocol investigators, and\u002For study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For study participation\n  * Diagnosed with a serious psychiatric condition\n\nSelf-Report Criteria\n\n* Received psychological or psychiatric care outside of INCan in the last 3 months\n* Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale\n* Too ill to participate determined by the question: \"Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?\"\n\nProvider Eligibility Criteria:\n\nInclusion Criteria Self-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded",{"count":360,"type":22},300,[362],"NA","The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.",[300,239,365,29,366,367,368,369,370,371,372,373],"Colorectal Cancer","Breast Cancer Stage III","Breast Cancer Stage IV","Prostate Cancer Stage III","Prostate Cancer Stage IV","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Thyroid Cancer Stage III","Thyroid Cancer Stage IV",[375,376,377,378,379,380,381,382,383,384,385,386,387,388],"Breast cancer","Breast cancer Stage III","Breast cancer Stage IV","Prostate cancer","Prostate cancer Stage III","Prostate cancer Stage IV","Colorectal cancer","Colorectal cancer Stage III","Colorectal cancer Stage IV","Thyroid cancer","Thyroid cancer Stage III","Thyroid cancer Stage IV","25-240","Memorial Sloan Kettering Cancer Center","2026-06-18",{"date":391,"type":37},"2026-06-22",{"date":393,"type":37},"2026-05-01",{"date":395,"type":22},"2029-04-13",{"name":388,"class":212},2,{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":419},"100516699","phase-2-a-study-of-avutometinib-and-defactinib-in-people-with-thyroid-cancer-100516699","NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer","Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients","Inclusion Criteria:\n\nCohort A will enroll RAIR, R\u002FM DTC patients with RAF dimer-driven disease.\n\nCohort B will enroll ATC patients with RAF dimer-driven disease.\n\n* Cohort A only: Patients must have pathologically or cytologically confirmed differentiated thyroid cancer of follicular origin (including papillary thyroid carcinoma, follicular thyroid carcinoma, hurthle cell carcinomas, poorly differentiated thyroid carcinoma and their respective variants).\n* Cohort B only: Patients must have anaplastic thyroid carcinoma.\n* Confirmation in a CLIA certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastases) possess at least one of the following genetic alterations: RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, Class 2 or 3 BRAF alterations (non-V600E\u002FK mutations or rearrangements).\n* Cohort A only: Evidence of progressive disease (e.g. presence of new or growing lesion(s) on radiologic imaging and\u002For new or worsening tumor-related symptoms) within 14 months of study enrollment.\n* Cohort A only: Patients must have recurrent or metastatic disease not amenable to curative surgery or radiation.\n* Patients with any number of prior therapies will be eligible.\n* Patients must have RECIST v1.1 measurable disease.\n* Age ≥ 18 years.\n* ECOG performance status of 0 or 1.\n* For Cohort A only: Patients must have not had recent treatment for thyroid cancer as defined as:\n\n  * No prior RAI therapy is allowed \\\u003C6 months prior to initiation of therapy on this protocol. A diagnostic study using \\\u003C10 mCi of RAI is not considered RAI therapy\n  * No external beam radiation therapy \\\u003C1 weeks prior to initiation of therapy on this protocol.\n  * No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed \\\u003C4 weeks prior to the initiation of therapy on this protocol\n* For Cohort A only: Patients must have RAI-refractory disease, defined as one of the following:\n\n  * Total lifetime dose of radioiodine \\> 600 mCi\n  * A tumor that is not radioiodine-avid on a diagnostic radioiodine scan performed\n  * A radioiodine-avid metastatic lesion which progressed despite radioiodine treatment given 6 months or more prior to study entry in the study. There are no size limitations for the index lesions used to satisfy this entry criterion\n  * The presence of at least one fluorodeoxyglucose (FDG) avid lesion.\n* Patients must be able to swallow and retain orally-administered pills without any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.\n* Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2.\n* Patients must have tissue from the primary tumor or metastases available for correlative studies. Either a paraffin block or at least 20 unstained slides are acceptable (30 unstained slides would be ideal). (If less than twenty unstained slides are available and a paraffin bloc is not available, the patient may be able to participate at the discretion of the investigator).\n* Patients must agree to undergo two research biopsies of (a) malignant lesion(s). Tumor tissue obtained prior to study consent or treatment as part of standard of care can also be submitted in lieu of performance of the first pre-treatment biopsy if the Principal Investigator deems it to be of sufficient quantity\u002Fquality\u002Ftimeliness. Patients may also be exempt from biopsy if 1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, 2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient (including if conduct of the biopsy will result in an unacceptable delay in therapy), or 3) the patient cannot be safely removed from anti-coagulation therapy (if the anti-coagulation therapy needs to be temporarily held for the biopsy procedure). If the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy. If the investigator deems a second research biopsy to be high risk after a patient has completed the first research biopsy, the patient may be exempt from the second biopsy. Biopsies of lesions that are in proximity to any vital neurovascular structures that can be considered high risk procedures will not be biopsied.\n* Baseline QTc interval \\\u003C 460 ms for women and ≤450 ms for men using Frederica's QT correction formula. NOTE: This criterion does not apply to patients with a right or left bundle branch block.\n* Adequate cardiac function wit left ventricular ejection fraction \\>50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan.\n* Screening laboratory values must meet the following criteria:\n\n  * WBC ≥ 2000\u002FμL\n  * Neutrophils ≥ 1000\u002FμL\n  * Platelets ≥ 100 x10\\^3 \u002FμL\n  * Hemoglobin \\> 9.0 g\u002FdL\n  * AST\u002FALT ≤ 2.5 x ULN (of \\\u003C 5x ULN in patients with liver metastases)\n  * Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n  * International normalized ratio (INR) \\\u003C 1.5 and partial thromboplastin time (PTT) \\\u003C 1.5 x ULN in the absence of anticoagulation or therapeutic levels in the presence of anticoagulation.\n  * Albumin ≥ 3.0 g\u002FdL (451 μmole\u002FL)\n  * Creatine phosphokinase (CPK) ≤ 2.5 x ULN\n  * Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 50 mL\u002Fmin (if using the Cockcroft-Gault formula below)\n  * Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg\u002FdL\n  * Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg\u002FdL\n\nExclusion Criteria:\n\n* Symptomatic untreated brain or leptomeningeal metastases Note: Patients with asymptomatic or treated brain or leptomeningeal metastases are allowed. Participants with symptomatic brain or leptomeningeal metastases after surgical and\u002Forg radiation therapy may be allowed with Principal Investigator approval.\n* Prior therapy with a MEK 1\u002F2 inhibitor or an inhibitor that targets Class II\u002FClass III BRAF alterations or a FAK inhibitor (with the exception of patients who received these therapies for a defined period of time to enhance radioiodine activity).\n* Patient who have had systemic investigational anti-cancer therapy within 4 weeks of the first dose of study therapy.\n* Major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or radiotherapy within 1 week of the first dose of study drug.\n* Treatment with warfarin. Patients on warfarin for deep vein thrombosis\u002Fpulmonary embolism should be converted to low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs).\n* Concomitant use of strong inhibitors and inducers of CYP3A4 (see Appendix 1 in Section 18). Patients should refrain from consumption of grapefruit, grapefruit juice and St. John's Wort, and other medications (with or without prescriptions), supplements, herbal remedies or foods that are strong inhibitors or inducers of CYP3A4 during treatment\n* Concomitant use of strong CYP2C9 inhibtors or inducers. For additional guidance see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-druginteractions-table-substrates-inhibitors-and-inducers\n* Concomitant use of strong P-glycoprotein(P-gp) inhibitors or inducers. For additional guidance see https:\u002F\u002Fwww.uptodate.com\u002Fcontents\u002Fimage\u002Fprint?imageKey=EM%2F73326\\&topicKey=HEME%2F1370\\&source=outlinelink\n* Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes.\n* Patients with a history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, such as an intraocular pressure \\> 21 mmHg\n* Treatment-refractory hypertension defined as a blood pressure of systolic \\>140 mmHg and\u002For diastolic \\>90 mmHg which cannot be controlled by anti-hypertensive therapy.\n* Patients with active hepatitis B infection (HBV surface antigen positive).\n* Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active Hepatitis C Virus (HCV). Testing for HIV or Hepatitis C prior to initiation of the study drug is not required. If a patient has a known history of treated HCV, then a viral load is required to confirm clearance of infection.\n* Known severe acute respiratory syndrome coronavirus 2 SARS-Cov2 infection (clinical symptoms) ≤28 days prior to first dose of study therapy.\n* History of rhabdomyolysis.\n* Concurrent congestive heart failure, prior history of class III\u002F IV cardiac disease (New York Heart Association \\[NYHA\\]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease.\n* Subjects with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease\n* Any other medical condition (e.g., cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the Investigator places the patient at unacceptably high risk for toxicity.\n* Patients who are pregnant or breastfeeding.\n* Patients with hypersensitivity to mannitol, magnesium stearate, HPMC (hydroxypropyl methylcellulose) shells",{"count":67,"type":22},[26],"The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects. Funding Source- FDA OOPD.",[29],[410,411,412],"Avutometinib","Defactinib","23-007",{"date":391,"type":37},{"date":415,"type":37},"2023-08-16",{"date":417,"type":22},"2027-08-16",{"name":388,"class":212},7,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":427,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":45},"100589951","phase-2-comparison-of-i-124-petct-for-the-diagnosis-of-thyroid-cancer-100589951","NCT06961084","Comparison of I-124 PET\u002FCT for the Diagnosis of Thyroid Cancer","Comparison of I-124 PET\u002FCT to I-123 Whole Body Imaging for the Diagnosis of Thyroid","Inclusion Criteria:\n\n1. Age \\>= 13 years.\n2. Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.\n3. Meeting criteria for one of the following two populations:\n\n   1. American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.\n   2. Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.\n4. Undergone total thyroidectomy.\n5. Planned I-123 imaging within 45 days after enrollment.\n6. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.","13 Years",{"count":429,"type":22},62,[26],"Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.",[29],[434],"Imaging Studies","2026-06-16",{"date":389,"type":37},{"date":438,"type":37},"2025-12-04",{"date":440,"type":22},"2028-04-01",{"name":442,"class":212},"Thomas Hope",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":483,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":510},"100499720","phase-1-phase-12-trial-of-s241656-in-selected-rasmapk-mutation--positive-malignancies-100499720","NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies","A Phase 1\u002F2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS\u002FMAPK Mutation-Positive Malignancies","Key Inclusion Criteria:\n\n* Life expectancy of ≥ 12 weeks in the opinion of the investigator.\n* Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.\n* Adequate bone marrow and organ function.\n* Recovered from toxicity to prior anti-cancer therapy.\n\nPart 1 Dose Escalation cohort ONLY:\n\n* Part 1A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations\n* Part 1B: Advanced\u002Fmetastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1C: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1E: Other advanced\u002Fmetastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations\n\nPart 2 Dose Optimization and Expansion cohorts ONLY:\n\n* Part 2A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations and\u002For BRAF mutations\n* Part 2A1: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations\n* Part 2A2: Advanced\u002Fmetastatic NSCLC with BRAF mutations\n* Part 2A3: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease\n* Part 2A4: Advanced\u002Fmetastatic NSCLC with a KRAS G12C mutation\n* Part 2B1: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B2: Advanced\u002Fmetastatic CRC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B3: Advanced\u002Fmetastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n\nKey Exclusion Criteria:\n\n* Cancer that has a known MEK1\u002F2 mutation.\n* Known allergy\u002Fhypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.\n* Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.\n* Major surgery within 4 weeks of study entry or planned during study.\n* Ongoing anticancer therapy.\n* Ongoing radiation therapy.\n* Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n* Clinically significant cardiovascular disease.\n* Symptomatic spinal cord compression.\n* Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n* Females who are pregnant or breastfeeding.\n* Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n* Prior use of experimental agents that target the KRAS\u002FBRAF\u002FMEK\u002FERK pathway.",{"count":451,"type":22},554,[25,26],"BDTX-4933-101 is a first-in-human, open-label, Phase 1\u002F2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced\u002Fmetastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced\u002Fmetastatic NSCLC with KRAS and\u002For BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.",[455,456,457,458,459,460,461,146,462,463,464,465,96,466,467,468,469,470,471,29,472,365,473,474,475,476,477,478,479,480,481,482],"Non-small Cell Lung Cancer","Histiocytic Neoplasm","Histiocytosis","BRAF Gene Mutation","BRAF V600E","BRAF V600 Mutation","BRAF Mutation-Related Tumors","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","Recurrent Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma","Solid Tumor","Solid Carcinoma","KRAS G12D","KRAS G12V","KRAS Mutation-Related Tumors","NRAS Gene Mutation","Thyroid Carcinoma","Colorectal Carcinoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Brain Metastases","Recurrent NSCLC","KRAS G13C","Acquired Resistance to KRAS G12C Inhibitor","KRAS G12A","KRAS G12F","KRAS G12R","KRAS G13D",[484,485,486,487,488,489,490,491,492,149,493,494,495,496,497,498,499,500,501],"BRAF Class I","BRAF Class II","BRAF Class III","KRAS","Intolerant histiocytic neoplasm","BDTX-4933","Phase 1","dose escalation","dose expansion","mitogen-activated protein kinase","RAS","RAF","Upstream oncogenic alterations","RAF inhibitor","intracranial disease","CRAF","NRAS","RAF fusions",{"date":503,"type":37},"2026-06-17",{"date":505,"type":37},"2023-04-18",{"date":507,"type":22},"2028-06",{"name":509,"class":212},"Institut de Recherches Internationales Servier",27,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":518,"targetDuration":520,"studyType":191,"phases":4,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":45},"100452547","environmental-factors-and-thyroid-cancer-100452547","NCT05172921","Environmental Factors and Thyroid Cancer","The Role of Environmental Factors in Thyroid Cancer","Inclusion criteria:\n\n* Bethesda category III, IV, V or VI following Fine Needle Aspiration; if a patient has a benign tumor following surgery, patient data\u002F samples will be stored to serve as benign control in potential future projects.\n* Age 18 years and older\n* Surgical candidate\n* Ability to provide informed consent\n\nExclusion criteria:\n\n* History of thyroid cancer\n* Completion surgery candidate\n* Pregnant women or other vulnerable patients (e.g. wards of the state, prisoners)",{"count":519,"type":22},500,"4 Years","Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using high quality diagnostic imaging explains only about 50% of this increased incidence, suggesting that there is a true increase in the occurrence of thyroid cancer and that changes in the prevalence of environmental risk factors might play a role in thyroid cancer etiology and progression. Yet, the cascade of environmental triggers linked to thyroid cancer remains elusive.\n\n'Exposomics' studies all health relevant chemical exposures that an individual experiences, and leverages metabolomic platforms to estimate the \"internal\" environment, informing both exogenous exposures and the metabolic products that lead to, or arise from, disease. Besides exposure to ionizing radiation as known modifiable risk factor, epidemiological evidence suggests that exposure to endocrine disrupting chemicals may be a potential thyroid cancer risk factor due to their known effects on thyroid function. However, these studies relied either on exposure questionnaires which are susceptible to recall bias, or used a limited set of targeted biomarkers measured after diagnosis for testing associations with case-control status, and not thyroid cancer prognosis. Further, the molecular basis for observed associations with thyroid cancer remains unclear.\n\nTo address the overall hypothesis that environmental exposures alter metabolic pathways and therefore affect thyroid cancer prognosis, small amounts of blood will be collected using dried blood microsampler technology (e.g. Mitra® sampling devices), which is minimally invasive and can be used to collect repeated blood measurements at home, without the need for specialized training. These dried blood samples will be used to perform metabolomics experiments, which describe the sum of exogenous exposures, metabolic alterations, and biological response. Additional exposure assessment will be performed using an exposure questionnaire. These results will be associated with thyroid cancer prognosis, e.g. disease-specific survival, disease recurrence, and mutational profiles, thus investigating the role of environmental exposures in the development of more aggressive forms of thyroid cancer.",[29],"2026-06-15",{"date":503,"type":37},{"date":526,"type":37},"2022-02-03",{"date":528,"type":22},"2035-06",{"name":530,"class":212},"Icahn School of Medicine at Mount Sinai",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":45},"100642663","phase-4-the-association-between-bilateral-intermediate-cervical-plexus-block-during-total-thyroidectomy-and-surgical-stress-response-100642663","NCT07600580","The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response","The Association Between Bilateral Intermediate Cervical Plexus Block and Salivary and Serum Biomarkers of Surgical Stress Response During Total Thyroidectomy","Inclusion Criteria:\n\n* patienets of both sexes\n* 18 years of age and older\n* ASA I or ASA II\n* euthyroid status\n* signed informed consent\n\nExclusion Criteria:\n\n* patients who refuse to sign the informed consent form\n* infection at the block injection site\n* hypersensitivity or contraindications to the medications used in the study\n* hypothyroidism or hyperthyroidism at the time of surgery\n* presence of substernal goiter\n* additional surgical interventions during the procedure\n* history of previous neck surgery or radiation\n* coagulopathy\n* uncontrolled respiratory disease\n* diabetes mellitus\n* autoimmune disease\n* chronic corticosteroid therapy\n* smokers\n* pregnant women.",{"count":539,"type":22},48,[541],"PHASE4","The aim of this study is to determine the impact of ultrasound-guided bilateral intermediate cervical plexus block on the surgical stress response in patients undergoing total thyroidectomy, as measured by the concentration of stress and inflammatory biomarkers in the participants' saliva and serum.\n\nThe study will be conducted on 48 subjects divided into two groups of 24: a control group receiving total intravenous anesthesia (TIVA) and an experimental group receiving TIVA combined with a bilateral intermediate cervical plexus block.\n\nInvestigators hypothesized that a combination of bilateral intermediate cervical plexus block and total intravenous anesthesia (TIVA) would reduce the surgical stress response, as measured by salivary and blood biomarkers, compared to TIVA alone in patients undergoing total thyroidectomy.\n\nShould the research confirm the hypothesis, it will provide an objective scientific argument for including the block in standard anesthetic protocols for total thyroidectomy surgeries, with the ultimate goal of reducing the surgical stress response and ensuring faster patient recovery.",[29,544,545,546],"Thyroid and Parathyroid Surgery","Hyperthyreosis and Goiter","Surgical Stress Response",[548,549,550,551],"bilateral intermediate cervical plexus block","surgical stress response","IL-6, cortisol, alpha-amylase","saliva analysis","2026-06-13",{"date":435,"type":37},{"date":555,"type":37},"2024-05-13",{"date":557,"type":22},"2027-08-01",{"name":559,"class":212},"University Hospital Dubrava",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":575,"leadSponsor":577,"locationsCount":4},"100641382","clinical-study-on-the-efficacy-of-laparoscopic-assisted-open-surgery-through-subclavian-approach-for-unilateral-thyroid-cancer-100641382","NCT07654322","Clinical Study on the Efficacy of Laparoscopic Assisted Open Surgery Through Subclavian Approach for Unilateral Thyroid Cancer","Multicenter Prospective Cohort Clinical Study on the Efficacy of Pneumoperitoneum-Free, Subclavian Transaxillary Laparoscopic-Assisted Versus Open Surgery for Unilateral Thyroid Cancer","Inclusion Criteria:\n\n1. Patients with newly diagnosed thyroid cancer aged ≥ 18 years and ≤ 70 years old;\n2. According to the latest ATA guidelines for the diagnosis and treatment of thyroid nodules and thyroid cancer in China, papillary thyroid carcinoma confirmed by histopathology has a clinical staging of cN0 in cervical lymph nodes.\n3. The patient has unilateral thyroid cancer with T1-T2 stage tumors, no lymph node metastasis, no extraglandular invasion, and no distant metastasis. They are willing to undergo surgical treatment for thyroid cancer;\n4. The surgical method is determined through joint consultation between the patient and the doctor;\n5. Participants voluntarily join this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Age\\>70 years old;\n2. Initial diagnosis of stage III-IV thyroid cancer;\n3. Thyroid cancer accompanied by abnormal thyroid function;\n4. The heart, lung, liver, kidney and other important organs have abnormal functions, and diabetes with poor control cannot tolerate surgery;\n5. The researcher believes that the patient is not suitable to participate in any other circumstances of this study.","70 Years",{"count":569,"type":22},400,"This study compares the clinical efficacy of non inflatable subclavian endoscopic surgery and open surgery for unilateral thyroid cancer, aiming to compare the differences in lymph node dissection rate, complication rate, surgical time, hospitalization time, drainage tube placement time and other indicators between the two surgical procedures, and provide guidance for surgical selection and safety in the later stage.\n\nThis study is a clinical controlled trial that plans to include 400 consecutive patients with thyroid cancer. After being fully informed and signing the informed consent form, the subjects will enter the trial period after being screened and qualified. The subjects will undergo non inflatable subclavian endoscopic thyroidectomy or open subclavian thyroidectomy according to their own wishes. The enrollment period is from March 2026-2028. The follow-up period should be at least 5 years.\n\nAfter the start of the experiment, a recruitment notice and corresponding recruitment manual will be issued, with a planned recruitment of 100 patients. The preparation stage for clinical research should include the preparation, distribution, and confirmation of research documents, as well as personnel training; Sign the informed consent form and screen the subjects. The surgical method for thyroid cancer is determined by the surgeon based on the patient's condition and after communication with the patient Evaluate the number of lymph nodes and metastatic lymph nodes in the central area by the pathology department, organize the operation time according to the surgical records, calculate the patient's drainage volume and hospitalization time according to the nursing records, and conduct telephone follow-up on patient satisfaction in the later stage.\n\nEstablish individual patient information using the existing thyroid cancer database in the department, recording general information, diagnosis and treatment history, and other relevant data.",[29],"2026-06-12",{"date":503,"type":37},{"date":52,"type":22},{"date":576,"type":22},"2031-02-28",{"name":578,"class":212},"Xijing Hospital",{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":264,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":45},"100266446","hereditary-risk-factors-for-thyroid-cancer-100266446","NCT02747888","Hereditary Risk Factors for Thyroid Cancer","Inclusion Criteria:\n\n* Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).\n* Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).\n* Individuals from families with a high suspicion of hereditary thyroid cancer:\n\n  * Families with a current or previous diagnosis of a thyroid cancer\u002Fnodule occurring in childhood (\\\u003C18 years old).\n  * Families with a high suspicion of hereditary thyroid cancer\u002Fnodules other than above to include:\n\n    * Families with thyroid cancer in multiple individuals\n    * Families with thyroid cancer and a known genetic syndrome\n    * Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)\n\nExclusion Criteria:\n\n* Individuals who are unable to give informed consent.\n* Individuals who are unable to complete study materials.",{"count":586,"type":22},250,[362],"Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.\n\n* In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.\n* Individuals with a past or present childhood thyroid cancer\u002Fnodule or a thyroid cancer suspected to be inherited in their family are invited to participate.",[29],[591],"Thyroid","2026-06-09",{"date":594,"type":37},"2026-06-11",{"date":596,"type":37},"2016-03-01",{"date":598,"type":22},"2029-03-01",{"name":600,"class":212},"Dana-Farber Cancer Institute",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":45},"100643094","development-and-application-of-an-ai-chatbot-for-perioperative-health-education-in-thyroid-cancer-patients-100643094","NCT07634978","Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients","Development and Application of an Artificial Intelligence Chatbot for Perioperative Health Education Among Thyroid Cancer Patients: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Diagnosed with thyroid cancer in accordance with the clinical diagnostic criteria, and confirmed by ultrasonography and histopathological examination.\n* Scheduled to undergo elective surgery for thyroid cancer.\n* Mentally competent to understand the study protocol, and voluntarily provided written informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Aged less than 18 years.\n* Concurrently diagnosed with malignant tumors in other organs or severe complications\u002Fdysfunctions of other major organs.\n* Patients who are anticipated to be unable to complete the study protocol due to plans for hospital\u002Fdepartment transfer, or high risk of treatment discontinuation.","60 Years",{"count":610,"type":22},150,[362],"The goal of this clinical trial is to evaluate the usefulness and effectiveness of a newly developed artificial intelligence (AI) chatbot for health education in thyroid cancer patients during the period around their surgery (the perioperative period). The main questions it aims to answer are:\n\nDoes the AI chatbot improve patients' readiness for discharge, quality of recovery, and active engagement in their own healthcare compared to traditional education methods?\n\nHow do patients rate the usability and friendliness of this new AI chatbot system?\n\nResearchers will compare a group of patients who receive traditional health education (the control group) with a subsequent group of patients who use the new AI chatbot built on the \"Coze\" platform (the intervention group) to see if the AI chatbot leads to better recovery experiences and higher patient engagement.\n\nParticipants will be asked to:\n\nAccess and interact with the AI chatbot to receive personalized health guidance, ask questions, and get instant feedback during their hospital stay.\n\nComplete a set of questionnaires on the morning of their hospital discharge to evaluate their recovery quality, readiness to leave the hospital, and level of engagement in their care.\n\nComplete an extra survey regarding the usability and acceptability of the chatbot system (only for participants in the AI chatbot group).",[29],"2026-06-03",{"date":592,"type":37},{"date":617,"type":37},"2026-01-01",{"date":619,"type":22},"2026-08-31",{"name":621,"class":212},"Tianjin Medical University Cancer Institute and Hospital",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":628,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":629,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":642,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":646,"locationsCount":648},"100405976","expanded-access-to-ulixertinib-bvd-523-in-patients-with-advanced-mapk-pathway-altered-malignancies-100405976","NCT04566393","Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","Inclusion Criteria:\n\n* Main Inclusion Criterion:\n\n  1\\. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations.\n* Other Inclusion Criteria:\n\n  1. In the opinion of the treating physician, the patient has exhausted or has inadequate response to available anti-cancer treatments.\n  2. In the opinion of the treating physician, the patient has adequate organ function to tolerate ulixertinib as defined in section 6.1\n  3. Male or female patients aged ≥ 12 years.\n  4. Patient must be able to swallow and retain orally administered medication.\n\n     Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients with any prior stomach or duodenal resection should be evaluated with that understanding.\n  5. For females, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients.\n  6. Highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration. In patients under the age of 18, who are not sexually active, abstinence is an acceptable form.\n  7. Toxicities related to any prior treatments are either stable, stable on supportive therapy, resolved, or in the opinion of the treating physician, clinically non-significant\n  8. Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the patient's age.\n\nExclusion Criteria:\n\n1. Patient is already participating in or qualifies for and is able to enroll in a clinical trial of ulixertinib (BVD-523).\n2. Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter.\n3. Patient has received radiotherapy within 14 days prior to the first dose of ulixertinib treatment other than for the allowable treatment of symptomatic bone metastasis.\n4. A history of current evidence\u002Frisk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)\n5. Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with ulixertinib due to safety concerns.\n6. Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with ulixertinib.\n7. Known hypersensitivity to ulixertinib or any component in its formulation.\n8. Patients taking prohibited medications as described in current Investigator's Brochure.\n\n   Note: Patients who require treatment with Drugs that are strong inhibitors or inducers of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of ulixertinib and should be discussed with xCures to review if any potential benefits outweigh the potential risks.\n9. Patient is actively breastfeeding.\n10. Prior stomach or duodenal resection that in the opinion of the treating physician would affect the breakdown and absorption of ulixertinib.","12 Years","EXPANDED_ACCESS","The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.\n\nUlixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.",[238,632,365,132,633,29,228,233,280,230,634,101,635,636,637,638,458,471,639,640,641],"Small Bowel Cancer","Non Small Cell Lung Cancer","Cholangiocarcinoma","Hepatocellular Carcinoma","Glioblastoma","MAPK Gene Mutation","KRAS Activating Mutation","HRAS Gene Mutation","MEK Mutation","ERK Mutation","AVAILABLE","2026-06-02",{"date":645,"type":37},"2026-06-04",{"name":647,"class":117},"xCures",26,{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":23,"phases":659,"briefSummary":660,"conditions":661,"keywords":662,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":674},"100370529","clinico-biological-database-in-patients-treated-with-metabolic-radiotherapy-in-the-nuclear-medicine-department-100370529","NCT04104529","Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department","Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department","BCB RIV","Inclusion Criteria:\n\n* Age ≥ at 18 years old,\n* Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy,\n* Patient treated as part of his treatment for:\n\n  * thyroid cancer,\n  * a neuroendocrine tumor or\n  * prostate cancer.\n* Patient having accepted the complementary blood sample,\n* Patient having given his informed, written and express consent.\n\nExclusion Criteria:\n\n* Patient not affiliated to a social security scheme,\n* Subject under tutelage, curatorship or safeguard of justice,\n* Patient in an emergency situation\n* Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons,\n* Pregnant and \u002F or breastfeeding woman",{"count":658,"type":22},350,[362],"Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.",[29,239,304],[663,664,665,666],"thyroid cancer","prostate cancer","neuroendocrine tumors","nuclear medecine",{"date":645,"type":37},{"date":669,"type":37},"2019-10-28",{"date":671,"type":22},"2026-10",{"name":673,"class":212},"Institut du Cancer de Montpellier - Val d'Aurelle",4,{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":682,"targetDuration":4,"studyType":23,"phases":684,"briefSummary":685,"conditions":686,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":397},"100589830","phase-2-zanzalintinib-for-the-treatment-of-advanced-thyroid-cancer-before-surgery-100589830","NCT06959511","Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery","ZAnzalintinib Neoadjuvant EValuation in Thyroid Oncology (ZANEVO)","Eligibility Criteria\n\n1. Participants with differentiated thyroid cancer, non-RET-mutated medullary thyroid cancer, or poorly differentiated thyroid cancer who present with locoregionally advanced disease, as defined by extrathyroidal and\u002For extra nodal extension, or with advanced recurrent\u002Fresidual invasive\u002Fbulky nodal disease will be enrolled in this trial, regardless of whether distant metastases are present or not.\n2. At least 18 years of age on the day of signing informed consent.\n3. Pathologic findings supporting the clinical impression of papillary thyroid cancer, follicular thyroid cancer, oncocytic thyroid cancer, medullary thyroid carcinoma, and\u002For poorly differentiated thyroid carcinoma. For patients with Bethesda IV or V FNA's (e.g. follicular neoplasm, follicular lesion, Hürthle cell neoplasm, Hürthle cell lesion), if the radiographic context is conclusive for carcinoma of thyroid origin, including significant extrathyroidal extension with invasion of surrounding structures and PET avidity, patients can be enrolled.\n4. Thyroid Neck Group morbidity complexity score of 1 to 4 (moderate, severe, very severe, or unresectable).\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with no known sudden deterioration 2 weeks prior to the first dose of trial treatment.\n6. Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy (e.g., physiological replacement of mineral corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy are permitted.\n7. Adequate organ and marrow function, based upon meeting all the following laboratory criteria within 28 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC)≥ 1500\u002Fmm3 (≥1.5 GI\u002FL) without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.\n   2. Platelets ≥ 100,000\u002Fmm3 (≥100 GI\u002FL) without transfusion within 2 weeks of screening laboratory sample collection.\n   3. Hemoglobin ≥9 g\u002FdL (≥90 g\u002FL) without transfusion within 2 weeks prior to screening laboratory sample collection.\n   4. International Normalized Ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤5 x ULN.\n   6. Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert fs disease ≤ 3 x ULN).\n   7. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin ( ≥0.67 mL\u002Fsec) using the Cockcroft Gault equation.\n   8. Urine protein-to-creatinine ratio (UPCR) ≤1 mg\u002Fmg ( ≤113.2 mg\u002Fmmol) creatinine.\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. For MD Anderson site only, subjects must be willing to undergo tumor biopsy prior to trial treatment, unless in the opinion of the treating physician, a biopsy is not feasible or safe. For all sites, subjects must be willing to ultimately undergo surgery if their tumor becomes surgically resectable. Subjects retain the right to refuse any research interventions.\n10. Sexually active fertile subjects and their partners must agree to use highly effective method of contraception (defined in Appendix A) during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods. (1) through 186 days after the last dose of zanzalintinib for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib for men.\n11. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n\nExclusion Criteria:\n\n1. Medullary thyroid cancer participants with germline RET or known somatic RET mutations.\n2. Prior treatment with zanzalintinib.\n3. Prior treatment with a tyrosine kinase inhibitor.\n4. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.\n7. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin inhibitors) and platelet inhibitors (e.g., clopidogrel).\n\n   Allowed anticoagulants are the following:\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n\n   Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.\n8. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n9. The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Unstable or deteriorating cardiovascular disorders: i. Congestive heart failure New York Heart Association class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes). ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment. iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n\n   iv. Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before to first dose of study treatment. Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Participants who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n10. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n11. Symptomatic cavitating pulmonary lesion(s) or endobronchial disease (asymptomatic or radiated lesions allowed. Intratracheal disease is allowed, as long as the endotracheal disease is not associated with major bleeding episodes.\n12. Lesions invading major blood vessel including, but are not limited to, inferior vena cava, pulmonary artery, or aorta. Note: Subjects with internal jugular vein involvement or tumor thrombus in the neck are eligible. Additionally, subjects with intravascular tumor extension (e.g., tumor thrombus in renal vein or inferior V. cava) may be eligiblefollowing Principal Investigator approval.\n13. Other clinically significant disorders that would preclude safe study participation.\n\n    1. Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n    2. Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)- related illness except for subjects meeting all of the following criteria: (1) on stable anti-retroviral therapy; (2) CD4+ T cell count ≥ 200\u002FμL; and (3) an undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: To be eligible, participants taking CYP inhibitors (e.g., zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts and viral load are monitored per standard of care by the local health care provider.\n    3. Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n    4. Malabsorption syndrome.\n    5. Uncontrolled symptomatic hyperthyroidism or hypothyroidism.\n    6. Uncontrolled symptomatic hypercalcemia or hypocalcemia.\n    7. Moderate to severe hepatic impairment (Child-Pugh B or C).\n    8. Requirement for hemodialysis or peritoneal dialysis.\n    9. History of solid organ or allogeneic stem cell transplant.\n14. Major surgery (as defined in Appendix B; e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Minor surgery (e.g., simple excision, tooth extraction) within 5 days before first dose of study treatment. Fine needle aspiration and core biopsies are allowed on study drug without drug hold.Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment.\n\n    Note: Participants with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n15. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment.\n16. History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n17. Pregnant or lactating females.\n18. Inability to swallow tablets or ingest a suspension either orally or by nasogastric (NG) or gastrostomy (PEG) tube.\n19. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n20. Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to Investigational Product, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.\n21. Other conditions, which in the opinion of the Investigator, would compromise the safety of the participant or the participants ability to complete the study.",{"count":683,"type":22},45,[26],"To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.",[687,29],"Neoadjuvant Treatment","2026-06-01",{"date":614,"type":37},{"date":691,"type":37},"2025-07-22",{"date":693,"type":22},"2030-10-01",{"name":695,"class":212},"M.D. Anderson Cancer Center",{"id":697,"slug":698,"hasResults":12,"nctId":699,"briefTitle":700,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":702,"targetDuration":4,"studyType":23,"phases":703,"briefSummary":704,"conditions":705,"keywords":707,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":717,"locationsCount":45},"100581542","phase-2-trop2-targeted-immunopet-imaging-of-solid-tumors-100581542","NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.",{"count":569,"type":22},[26,336],"This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[466,467,706,228,239,272,292,234,634,101,229,100,29,233],"Uroepithelial Carcinoma",[708,709,466],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","2026-05-27",{"date":712,"type":37},"2026-05-29",{"date":714,"type":37},"2024-12-23",{"date":716,"type":22},"2027-12",{"name":718,"class":212},"RenJi Hospital",{"id":720,"slug":721,"hasResults":12,"nctId":722,"briefTitle":723,"officialTitle":724,"acronym":4,"eligibilityCriteria":725,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":726,"targetDuration":4,"studyType":23,"phases":728,"briefSummary":729,"conditions":730,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":735,"lastUpdatePostDateStruct":736,"startDateStruct":738,"completionDateStruct":740,"leadSponsor":742,"locationsCount":45},"100567833","phase-1-brodalumab-in-the-treatment-of-immune-related-adverse-events-100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":727,"type":22},11,[25],"The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[300,230,285,272,29,731,238,732,733,274,275,233,734,234,296,239,243,466],"Gynecologic Cancer","Stomach Cancer","Brain Tumor","Oral Cancer","2026-05-11",{"date":737,"type":37},"2026-05-13",{"date":739,"type":37},"2025-03-11",{"date":741,"type":22},"2027-11",{"name":743,"class":212},"Brian Henick, MD",{"id":745,"slug":746,"hasResults":12,"nctId":747,"briefTitle":748,"officialTitle":749,"acronym":4,"eligibilityCriteria":750,"healthyVolunteers":12,"sex":751,"minAge":18,"maxAge":269,"enrollmentInfo":752,"targetDuration":4,"studyType":23,"phases":753,"briefSummary":754,"conditions":755,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":757,"lastUpdatePostDateStruct":758,"startDateStruct":760,"completionDateStruct":762,"leadSponsor":763,"locationsCount":45},"100633291","ganoderma-spores-modulate-the-gut-brain-axis-100633291","NCT07524777","Ganoderma Spores Modulate the Gut-Brain Axis","Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Outpatients at Zhejiang Cancer Hospital with histologically confirmed papillary thyroid carcinoma (post-surgery) and depressive symptoms (HAMD-24 score ≥ 8, confirmed by a clinical psychologist).\n* Han Chinese ethnicity.\n* No history of depression or other psychiatric disorders.\n* Age 18-80 years.\n* Female.\n\nExclusion Criteria:\n\n* Suffering from other gastrointestinal system diseases.\n* History of gastrointestinal surgery prior to intervention.\n* Including those with other concurrent malignancies requiring chemotherapy, radiotherapy, biological therapy, or traditional Chinese medicine treatment.\n* Received antibiotic treatment or microecological modulators within 3 months prior to intervention.\n* Acute intestinal obstruction.\n* Patients who are currently taking antidepressant medication, or those whom the investigators judge require immediate initiation of antidepressant medication treatment.\n* Organic brain diseases, brain trauma.\n* History of psychiatric disorders, use of psychoactive substances (e.g., drugs).\n* Severe liver or kidney dysfunction.\n* Pregnancy or lactation.","FEMALE",{"count":360,"type":22},[362],"This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g\u002Fday) or matched placebo.",[756,29],"Depression","2026-05-07",{"date":759,"type":37},"2026-05-12",{"date":761,"type":37},"2026-04-11",{"date":619,"type":22},{"name":764,"class":212},"Ling Zhiqiang"]